VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond. Cancer Res. 2023 10 02; 83(19):3159-3161.
View in:
PubMed
subject areas
Breast Neoplasms
Carcinoma, Non-Small-Cell Lung
Estrogen Receptor alpha
Female
Humans
Lung Neoplasms
Proto-Oncogene Proteins c-ret
authors with profiles
VIVEK SUBBIAH